Slides
Page 1
Second Quarter 2026 Earnings Investor Presentation July 30, 2026
Page 2
This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2026 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” “vision,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control and are subject to various risks and uncertainties, including those described below. Among other things, there can be no assurance that Omnicell’s actual results will not differ, perhaps substantially, from the targets and expectations contained in this presentation. Such statements also include, but are not limited to, Omnicell’s projected product bookings, annual recurring revenues, revenues, including product, service, technical services and SaaS and Expert Services revenues, respectively, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding our planned and existing products and services, developing new or enhancing existing products and solutions, including, Omnicell Titan XT and OmniSphere, and the related objectives and expected benefits (and any implied financial impact); our ability to deliver sustainable and profitable growth; our ability to expand our market presences, scale recurring revenue and accelerate our technology platform, and statements about Omnicell’s strategy, plans, objectives, vision, purpose and guiding principles, goals, including its innovation, environment, social and governance goals and strategies, market or Company outlook, planned investments, and growth opportunities. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including longer timeframes for purchasing decisions and entering into agreements for our products or solutions, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) Omnicell’s ability to successfully achieve anticipated growth targets or market adoption, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, including the variability and difficulty in predicting purchasing decisions, for both current customers and competitive conversion opportunities being, difficulty forecasting product bookings due to the size and mix of potential customer opportunities or that the announcement of Titan XT may influence or impact purchasing decisions, including the timing of those decisions, (vi) delays, technical challenges and unexpected or greater than anticipated expenses associated with developing new products and services or failing to achieve technological or economic feasibility, obtain regulatory approval or gain market acceptance, (vii) the potential impact of periods of significant volatility due to geopolitical developments, (viii) the risk of increased credit, collection, and operational challenges from providing lease financing options to our customers, (ix) risks related to the incorporation of artificial intelligence technologies, including generative or agentic AI technologies, into our products, services and processes or our vendors offerings, (x) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xi) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (xii) Omnicell’s ability to meet the demands of, or maintain relationships with, GPOs and its institutional, retail, and specialty pharmacy customers, (xiii) the inability to secure or maintain access to existing and future specialty drugs or pharmacy provider networks for our specialty pharmacy customers, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses or technologies and successfully integrate such acquisitions, (xvi) Omnicell’s substantial debt, (xvii) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (xviii) changes to the 340B Program, (xix) our international operations may subject us to additional risks, including from the impact of tariffs, (xx) covenants in our credit agreement could restrict our business and operations, (xxi) exposure to liquidity and counterparty risk as a result of financial institution and money market fund concentration, (xxii) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (xxiii) catastrophic events, (xxiv) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xxv) Omnicell’s ability to protect its intellectual property, (xxvi) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxvii) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxviii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxix) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxx) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Readers are encouraged to review this press release in conjunction with our most recent Annual Report on Form 10-K and our other reports filed with or furnished to the SEC. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.Non-GAAP Financial InformationThis presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), including Q2 ’26 non-GAAP gross margin, non-GAAP operating expenses, non-GAAP EBITDA, and non-GAAP diluted earnings per share, guidance with respect to 2026 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the Q2 ‘26 non-GAAP financial measures to the most directly comparable GAAP measures are included in the Appendix to this presentation. Our 2026 guidance for non-GAAP EBITDA and non-GAAP earnings per share, exclude certain items, which include, but are not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes. These excluded items may be significant. We do not provide a reconciliation of forward-looking non-GAAP guidance or targets to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. We believe such a reconciliation would imply a degree of precision that could be confusing or misleading to investors. These items may also have a material impact on GAAP earnings per share and GAAP net income in future periods. As such, these forward-looking non-GAAP financial measures are limited in their utility for evaluating our future operating results in accordance with GAAP.OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one its subsidiaries.© 2026 Omnicell, Inc. 2 Forward-Looking Statements
Page 3
© 2026 Omnicell, Inc. 3 Investor Presentation – July 30, 2026 Our Guiding PrinciplesOur PurposeTo be the healthcare providers’ most trusted partner to enable the Autonomous Pharmacy transformation Our Guiding Principles represent what we stand for as a company, guiding us in every aspect of how we do business. oPassionate TransformeroRelationships MatteroIntellectually CuriousoMission DrivenoEntrepreneurialoDo the Right Thing
Page 4
© 2026 Omnicell, Inc. 4 Omnicell Investment HighlightsInvestor Presentation – July 30, 2026 A recognized leader in medication management with a 30-year track record and an installed base that includes more than one-half of the top 300 U.S. health systems* Investing in SaaS and Expert Services in an effort to drive growth in recurring revenue, projected to be 22% of total revenue in 2026 Strong balance sheet should support growth initiatives and help drive sustainable and profitable growth Executing on our vision to deliver autonomous medication management solutions that enhance customer outcomes and to create stakeholder value With Omnicell Titan XT, powered by our OmniSphere platform, Omnicell is investing in a next generation automated dispensing system that is built to support evolving healthcare needs while delivering greater pharmacy control and nursing confidence for a growing enterprise *As defined by Definitive Healthcare.
Page 5
© 2026 Omnicell, Inc. 5 Omnicell’s Growth Strategy is to:Investor Presentation – July 30, 2026 CONNECTthe health network GROWwhere care is being delivered DISRUPTpharmacy care with innovation
Page 6
© 2026 Omnicell, Inc. Our StrategyInvestor Presentation – July 30, 2026 HEALTH SYSTEMOUTPATIENT Central Pharmacy/Centralized Service CenterIV RoomPoints of Care Specialty PharmacyAmbulatory Care Omnicell is focused on delivering autonomous medication management solutions designed to help healthcare facilities worldwide to improve efficiency and enhance patient safety across all settings of care. Guided Software WorkflowsIntended to provide greater visibility to medication inventory and usage, which should provide powerful data insights Smart Devices & Robotics Technology designed to automate manual tasks to enhance safety and optimize labor AnalyticsConnected intelligence intended to drive data-driven performance optimization Expert ServicesOnsite and remote experts dedicated to optimizing your technology in an effort to deliver outcomes6
Page 7
The Autonomous PharmacyInvestor Presentation – July 30, 2026 Industry-Defined Vision Replace manual, error-prone activities with automated processes that are designed to be safer and more efficient.oZero medication errorsoZero medication wasteoZero human touches until delivery to patiento100% regulatory complianceo100% data and inventory visibilityo100% pharmacist’s time on clinical activities American Journal of Health-System Pharmacy, Volume 78 Issue 7, April 2021 © 2026 Omnicell, Inc. 7
Page 8
© 2026 Omnicell, Inc. 8 Investor Presentation – July 30, 2026 OUTCOME DELIVERED 25,000Errors Annually in Hospitals1 $745BUncompensated medical care over 20 years2 $39B Spent in compliance administration3 88%Hospitals report technician deficits4 75%Pharmacists’ tasks are non-clinical3 Less pharmacist time spent on distribution tasks5 Cost savings from dose optimization and reduction of 503B spend5 Reduction of nurse medication retrieval time5 Access to limited distribution drugs5 Barcode scanning through Central Pharmacy robotics supports enhanced safety and accuracy5 75% $2.8M 54% 97% 100% 1.Poon, China, Churchill, et al. Ann Intern Med 2006; 145(6):426–434.2.https://www.aha.org/fact-sheets/2020-01-06-fact-sheet-uncompensated-hospital-care-cost; Total cost of uncompensated care from 2000–20203.Autonomous Pharmacy White Paper and Industry publications 4.https://www.uspharmacist.com/article/a-review-of-the-hospital-pharmacist-shortage5.Omnicell internal analysis. Data on file. CHALLENGE Delivering Solutions Designed to Support Customer Operational and Economic Environments
Page 9
© 2026 Omnicell, Inc. 9 Revenue Growth DriversInvestor Presentation – July 30, 2026 Deep Customer Relationships and Robust Product Backlog and Annual Recurring RevenueoStrong position with more than one-half of the top 300 U.S. health systems oRobust Product Backlog of $640M as of 12/31/2025oAnnual Recurring Revenue of $636M as of 12/31/2025 Multiple Growth Drivers oExpanding Our Market Presence Expanding our footprint within our existing customer base and increasing market adoption of our products and solutions oScaling Recurring Revenue Grow our predictable recurring revenue base by increasing market adoption and delivering long-term value to customersoAccelerating Our Technology PlatformOmniSphere, a cloud-native platform that is designed to be the connected backbone for all Omnicell products, beginning on nursing floors with the launch of Omnicell Titan XT
Page 10
© 2026 Omnicell, Inc. 10 Why We Believe Omnicell is Positioned to WinInvestor Presentation – July 30, 2026 Omnicell has the right solutions and the right business model to solve the medication managementproblem that the healthcare system is facing Omnicell has a proven track record of innovation as the leading strategic partner to health systems in large and growingmarket segments Omnicell is scaling SaaS and Expert Services to capitalize on the many growth opportunities ahead — with SaaS and Expert Services continuing to drive recurringrevenue growth Continued investment in new products and solutions, including Omnicell Titan XT and OmniSphere to drive long-term sustainable growth. Executing on our goal to advance autonomous medication management
Page 11
Omnicell Innovation
Page 12
© 2026 Omnicell, Inc. 12 Delivering End-to-End Medication Management Across the Care Continuum TodayInvestor Presentation – July 30, 2026 Powered by the OmniSphere platform Connected devices, or automation equipmentKEY Managed serviceCloud, or embedded software XR2 Automated Dispensing System Auto Packagers Carousels IVX Station XT SupplyXT Anesthesia WorkstationControlled Substance ManagerXR2 Automated Dispensing System Carousels IVX Station IVX Workflow E3 Single Dose Automation MTS-500 MTS-350 Titan XT Inventory Optimization Service Central Medication Automation ServiceAnywhereRNColorTouchClosed-LoopSinglePointeInventory Optimization ServiceInventory Optimization ServiceCentral Pharmacy Manager IV Compounding Service IVX Analytics IVX Manager MedVision340B TPASpecialty Pharmacy ServicesGuided PackingIntelligent voice response solutionTargeted patient communicationsMedication synchronization & adherenceMedical billings & reconciliation Centralized Service CentersCentral Pharmacy Clinical/OfficesSpecialty PharmacyLong-Term Care Point of Care Retail Pharmacy IV Room OmniSphere Represents planned technology under development or that may be under development in the future and not currently generally available to Omnicell customers. Omnicell makes no commitment with regard to such potential future technology, its potential features or its future availability and it remains subject to change at Omnicell’s discretion. Diversion ManagementDiversion Management
Page 13
© 2026 Omnicell, Inc. 13 Powered by OmniSphereInvestor Presentation – July 30, 2026 As Omnicell’s secure cloud platform, OmniSphere is designed to be the connected backbone of medication management, providing scalability, one source of truth, interoperability with EHRs, and advanced intelligence to unify Omnicell devices and power a connected enterprise. Safe with leading security and compliance standards Smart decisions with broad visibility and analytics Connectedautomation across the care continuum OmniSphere is currently under development and not yet generally available to Omnicell customers. Omnicell makes no commitment with regard to such potential future development, features or availability, and it remains subject to change at Omnicell’s discretion
Page 14
Simple & IntelligentAutomated workflows aim to reduce pharmacy task steps, while intelligent alerts are engineered to guide safer nursing decisions. Built-in device health monitoring enables proactive support before issues impact operations.Protected HITRUST-certified security designed toprotect patient data. Intelligent nursing safeguards meant to prevent medication errors. Engineered for backwards compatibility with existing XT cabinets in an effort to protect infrastructure investments. Built for the modern needs of Health SystemsOmnicell Titan XT Automated Dispensing System (ADS) is engineered to streamline pharmacy workflows, enhance nursing safeguards, and simplify IT operations through intelligent, enterprise-ready automation.Enterprise Edition Centralized cloud management is designed to enable system-wide changes across users, formularies, and care settings – to unify control across your entire medication management ecosystem. © 2026 Omnicell, Inc. 14 Introducing Titan XT on OmniSphereInvestor Presentation – July 30, 2026 Omnicell Titan XT is currently under development and not yet generally available to Omnicell customers. Omnicell makes no commitment with regard to such potential future development, features or availability, and it remains subject to change at Omnicell’s discretion
Page 15
© 2026 Omnicell, Inc. 15 Titan XT – Reimagined Smart WorkflowsInvestor Presentation – July 30, 2026 Cabinet interactions are streamlined through user-specific guided workflows, which should enable staff to focus on high-priority tasks with greater efficiency and reduced cognitive load. Automated Workflows should remove the need to run and evaluate manual reports Up to 75% reduction in steps to initiate pharmacy workflows like restock, recalls and unassigning expirations. 1 Designed to drastically reduce the time to end user proficiency 1. Omnicell Internal analysis. Data on file.Omnicell Titan XT is currently under development and not yet generally available to Omnicell customers. Omnicell makes no commitment with regard to such potential future development, features or availability, and it remains subject to change at Omnicell’s discretion.
Page 16
© 2026 Omnicell, Inc. 16 Omnicell Titan XT – Focused on Improving Outcomes and User ExperienceInvestor Presentation – July 30, 2026 Look-alike, sound-alike alertsCritical alert frameworkCustom alert frameworkOverride reason matching alert DynamicRestockGive technicians clear task visibility and managers real-time completion tracking, even when workflows are interrupted FiveRightsIntended to ensure the five rights of medication administration are easy for nurses with specific prompts meant to get the right medication to the right patient → → Restocking by taskVisual bin assignmentRecall managementExpiration managementReturn bin auditing Omnicell Titan XT is currently under development and not yet generally available to Omnicell customers. Omnicell makes no commitment with regard to such potential future development, features or availability, and it remains subject to change at Omnicell’s discretion.
Page 17
Product Overview
Page 18
© 2026 Omnicell, Inc. 18 Points of CareInvestor Presentation – July 30, 2026 XT Automated Supply Dispensing CabinetsXT Anesthesia WorkstationInventory Optimization ServiceOmnicell Titan XT and XT Series Automated Dispensing System As the final step in the pharmaceutical administration process, the bedside exchange of medication from nurse to patient is critical to care success. However, countbacks, restocks, reconciliation, and other manual tasks may force nurses to spend more time managing medications and less time on clinical care. Omnicell seeks to optimize medication management at the points of care so clinicians can focus on the real priority—patients.
Page 19
© 2026 Omnicell, Inc. 19 Central PharmacyInvestor Presentation – July 30, 2026 Pharmacy CarouselInventory Optimization ServiceCentral Pharmacy Dispensing Service Central pharmacy is the medication dispensing hub of most hospitals. Roadblocks that surface here have the potential to impact patient safety, care, and clinical workflows throughout the health system. Omnicell automates manual dispensing tasks in an effort to reduce errors and waste, improve accuracy, and give valuable human resources more time to focus on the work that matters most—patient care.
Page 20
© 2026 Omnicell, Inc. 20 IV RoomInvestor Presentation – July 30, 2026 IVX WorkflowIV Compounding Service Accuracy and sterility in IV compounding are paramount to patient safety, but an overreliance on 503B outsourcing and manual in-house systems often creates unnecessary risk and expense. Omnicell’s advanced automation tools including sterile compounding robotics and semi-automated workflow management are designed to support more accurate, safe, and cost-effective IV compounding.
Page 21
© 2026 Omnicell, Inc. 21 Specialty PharmacyInvestor Presentation – July 30, 2026 Omnicell 340BSpecialty Pharmacy Services As medical innovations create new, more complex drugs, many pharmacies need specialized tools and expertise to help manage the patient’s treatment journey. Opening or optimizing an in-house specialty pharmacy often requires unique capabilities to navigate the demands of high-cost, high-touch medications. Omnicell seeks to deliver the technology and know-how to help customers accelerate and maximize specialty pharmacy outcomes.
Page 22
© 2026 Omnicell, Inc. 22 EnlivenHealth®Investor Presentation – July 30, 2026 Optimizing a patient’s medication journey often means extending care beyond the inpatient setting and enhancing the processes of retail and community pharmacies. Through EnlivenHealth®, Omnicell provides patient engagement software and omnichannel communications that is designed to empower retail pharmacies and health plans to promote optimal health of patient and member communities while improving their performance.
Page 23
© 2026 Omnicell, Inc. 23 Medication AdherenceInvestor Presentation – July 30, 2026 Packaging EquipmentAutomationPackaging and Labeling Solutions Through industry-leading packaging and automation solutions, Omnicell Medication Adherence helps to empower pharmacies to work more efficiently as they seek to and improve medication safety and effectiveness for customers and patients.
Page 24
Second Quarter 2026Financial Highlights
Page 25
© 2026 Omnicell, Inc. 25 Financial SnapshotInvestor Presentation – July 30, 2026 Q2 ’26YoY Change Total Revenues$312 million7%Non-GAAP Gross Margin %50.2%550 bpsNon-GAAP Operating Expenses$104 million(2%)Non-GAAP EBITDA$67 million75%Non-GAAP Diluted Earnings Per Share$0.94109% See Appendix for a reconciliation of Q2 ‘26 Non-GAAP Gross Margin, Q2 ‘26 Non-GAAP Operating Expenses, Q2 ’26 Non-GAAP EBITDA and Q2’26 Non-GAAP Diluted Earnings Per Share to their most directly comparable GAAP financial measures.
Page 26
© 2026 Omnicell, Inc. 26 Total Year Revenue CompositionInvestor Presentation – July 30, 2026 1.Connected Devices and Software Licenses include, but are not limited to, XT Series automated dispensing systems and products related to Central Pharmacy Dispensing Service and IV Compounding Service.2.Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions. GAAP ($Million)Recurring vs Non RecurringCategoryActual 1Q26Actual 2Q26Guidance TY–2026TY 2026 YoY Change %(Mid-Point) Connected Devices and Software Licenses1Non RecurringProduct$149$149$690–$7004%ConsumablesRecurring Product $26$26 Technical ServicesRecurring Service $67$68$267–$2724% SaaS and Expert Services2 Recurring Service $68$69$268–$2734% Total Revenue $310$312$1,225–$1,2454% SaaS and Expert Services % of Total Revenue22%22%22% Recurring % of Total Revenue 52%52%
Page 27
© 2026 Omnicell, Inc. 2026 GuidanceInvestor Presentation – July 30, 2026 Long-Term Value Creation OpportunitiesoLeadership position in the digital transformation of healthcareoOmnicell’s Titan XT is designed to combine proven automation and powerful intelligence to deliver an enhanced medication management experienceoOmniSphere, a cloud-native platform designed to enable enterprise-wide medication visibility and simplify access to automation and intelligence toolsoPlatform adoption, expansion, market share gains, and upgrade cycles supporting growth oStrong balance sheet should enable transformation to new business model Q3–2026TY–2026Product bookingsNot guided$425–$560 millionARR Not guided$660–$680 millionTotal Revenues$301–$307 million$1.225–$1.245 billionProduct Revenues$169–$172 million$690–$700 millionService Revenues$132–$135 million$535–$545 millionTechnical Services RevenuesNot guided$267–$272 millionSaaS & Expert Services RevenuesNot guided$268–$273 millionNon-GAAP EBITDA$32–$37 million$175–$185 millionNon-GAAP EPS$0.35–$0.43$2.15–$2.30 We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. 27
Page 28
© 2026 Omnicell, Inc. An Outcomes-Based Approach to ESGInvestor Presentation – July 30, 2026 EnvironmentaloContinued our efforts to reduce our environmental footprint and energy consumption, realizing decreases in both emissions and energy useoCompleted a new climate risk assessment in 2025, including a review of our previous climate risk assessments to identify potential gaps and recommend next steps in response to the changing regulatory landscapeoAdvanced our efforts to reuse packaging and shipping materials and reduce packaging wasteSocialoRenewed our focus on employees through the establishment of a new strategic pillar, Unleash the Power of Our People, and executed on initiatives to help advance a high-performing cultureoLaunched programs to support leadership development, like the Lead Program, Leader as Coach, and the Development Circles ProgramoDonated innovative pharmacy care solutions to strengthen the global healthcare infrastructure and raised awareness and generated community support among employees for numerous health issues, including kidney health, heart health, breast cancer awareness, domestic violence awareness, and moreGovernanceoLaunched XT Amplify, a multi-year innovation program designed to improve customers’ pharmacy and nursing efficiency and reduce medication errors and wasteoStrengthened industry connections through educational initiatives and industry events such as Illuminate and ASHP Midyear Clinical MeetingoRedesigned customer education to be solution-focused to facilitate a more holistic use of Omnicell solutions and implemented an improved escalation process for addressing customer concerns`1. ISS ESG ”Prime” rating calculated as of September 26, 2025 1 28 Awarded Best Sustainability Reporting (Small Cap) 2024 ESG ReportPublished fifth annual ESG Report in April 2025 89%of Board is independent
Page 29
Appendix
Page 30
© 2026 Omnicell, Inc. 30
Page 31
© 2026 Omnicell, Inc. 31 (a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2026 and 2025.
Page 32
© 2026 Omnicell, Inc. 32 (b) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments.